Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ad.p53-DC vaccine |
Synonyms | |
Therapy Description |
INGN-225 (Ad.p53-DC vaccine) is an adenoviral-p53 dendritic cell vaccine, which potentially induces a cytotoxic immune response against tumor cells over expressing Tp53 (PMID: 20420527). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ad.p53-DC vaccine | INGN-225 | p53 Vaccine 5 | INGN-225 (Ad.p53-DC vaccine) is an adenoviral-p53 dendritic cell vaccine, which potentially induces a cytotoxic immune response against tumor cells over expressing Tp53 (PMID: 20420527). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 wild-type | ovarian cancer | predicted - sensitive | Ad.p53-DC vaccine | Phase I | Actionable | In Phase I and Phase II clinical trials, various forms of p53 gene therapy (such as adenoviral-p53) have been shown to be generally safe and have demonstrated clinical efficacy in patients with ovarian cancer (PMID: 12082455; PMID: 19621448; PMID: 21927947; PMID: 15297186; PMID: 12082456). | 15297186 21927947 19621448 12082455 12082456 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|